A groundbreaking new treatment for multiple myeloma patients whose cancer has stopped responding to existing therapies is now available on the NHS in England, following a successful pricing agreement that could offer hope to thousands facing this challenging blood cancer.
Teclistamab has been approved specifically for patients with relapsed and refractory multiple myeloma - meaning their cancer has returned after initial treatment and hasn't responded to follow-up therapies. For these patients, treatment options become increasingly limited, making this approval particularly significant. The drug works as a bispecific antibody, engineered to act like a bridge between cancer cells and the body's own immune system. It binds to both the myeloma cells and the patient's T-cells, bringing them together so the immune system can better recognise and destroy the cancer.
Multiple myeloma is the second most common blood cancer in the UK, affecting around 6,000 people each year. Whilst treatment advances have improved outcomes considerably, the condition remains incurable, with patients typically experiencing periods where the disease is controlled, followed by relapse. Having new treatment options like teclistamab available through the NHS is vital for extending life and maintaining quality of life when standard treatments are no longer working effectively.
The drug's availability follows the rigorous assessment process overseen by the National Institute for Health and Care Excellence (NICE), which evaluates both clinical effectiveness and cost-effectiveness. The successful commercial agreement between NHS England, NICE, and the manufacturer means patients can now access this treatment without the financial barriers that often prevent access to innovative cancer drugs.
For patients, this represents access to a potentially life-extending treatment that was previously unavailable on the NHS. Whilst specific eligibility criteria will apply - determined by specialist teams based on individual circumstances and the drug's licence conditions - it offers renewed hope for those with advanced disease. If you're living with multiple myeloma and believe you might benefit from this treatment, discuss the options with your haematologist or oncology team at your next appointment.
Source: BBC